Questions:

1. In patients who have received chemo immunotherapy ad first line treatment for advanced NSCLC, would you consider a re-challenge with two immunotherapies as an option? (patients who did not experience any irAE)
2. In case of First line Immunotherapy alone, would you consider chemo immunotherapy in second line or chemotherapy alone? (patients who did not experience any irAE)
3. In case of progression after first line, do you recommend a re-biopsy?
4. What is you preferred second line treatment of choice after chemo-immunotherapy?
5. In case a patient experienced response to chemotherapy +immunotherapy in first line and progresses on immunotherapy maintenance, would you re-challenge the patient with the same chemotherapy given in first line?